INTEC PHARMA LTD.
INTEC PHARMA LTD. (NTEC): 2 pipeline candidates · ~8 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.0 months
D/E 0.54 · 0% dilution
Lead: Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for INTEC PHARMA LTD.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$11.1M
Quarterly Burn
$4.3M
Runway
8.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| ap-cannabinoids | Phase 1 |
| ap-cd/ld | Phase 3 |
Frequently asked questions
How many drug candidates are in INTEC PHARMA LTD.'s pipeline?
INTEC PHARMA LTD. (NTEC) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is INTEC PHARMA LTD.'s lead drug candidate?
INTEC PHARMA LTD.'s most advanced tracked candidate is ap-cannabinoids (Phase 1) for Various pain indications.
What is INTEC PHARMA LTD.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, INTEC PHARMA LTD. has approximately 8.0 months of cash runway.
Who is the CEO of INTEC PHARMA LTD.?
William B. Hayes is the chief executive officer of INTEC PHARMA LTD. (NTEC).
Get the full picture on INTEC PHARMA LTD.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.